The impact of human leukocyte antigen (HLA) donor-specific antibodies (DSA) upon cord blood (CB) engraftment is controversial. We evaluated the influence of pre-existing HLA-antibodies (HLA-Abs) on engraftment in 82 double-unit CB recipients (median age 48 years) transplanted for hematologic malignancies. Of 28 patients (34%) with HLA-Abs, 12 had DSA (median MFI 5,255, range 1,057–9,453). DSA patients had acute leukemia (n = 11) or myelodysplasia (n = 1) and all received either high-dose or reduced intensity (but myeloablative) conditioning. After myeloablative CBT (n = 67), sustained donor engraftment was observed in 95% without HLA-Abs (median 23 days), 100% with non-specific HLA-Abs (median 23 days), and 92% with DSA (median 31 days, p = 0.48). Of 6 patients with HLA-Abs to one unit, 3 engrafted with that unit and 3 with the other. Of 6 patients with HLA-Abs against both units, one had graft failure despite being 100% donor, and 5 engrafted with one unit. Successful donor engraftment is possible in patients with DSA after myeloablative double-unit CBT. Our data suggest potential deleterious effects of DSA can be abrogated in patients with hematologic malignancies.